HER2-Positive Breast Cancer Market Expected To Grow At 6.8% CAGR Through 2030: What Businesses Need To Know

HER2-Positive Breast Cancer Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

HER2-Positive Breast Cancer Market Size, Value And Growth Trajectory Through 2030

The her2-positive breast cancer market size has demonstrated robust growth over recent years. It is anticipated to expand from $10.93 billion in 2025 to $11.7 billion in 2026, at a compound annual growth rate (CAGR) of 7.1%. The historical increase can be attributed to the rising identification of her2-positive cases, the expansion of targeted oncology drug approvals, developments in hospital oncology infrastructure, the availability of monoclonal antibody therapies, and heightened clinical trial activity.

The her2-positive breast cancer market size is projected to undergo significant expansion in the coming years, anticipated to reach $15.23 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. The projected growth during this period stems from factors such as the increasing adoption of next-generation her2 inhibitors, the broadening penetration of biosimilars, a rising demand for precision oncology treatments, growing investment in targeted cancer research, and an increased focus on improving patient survival outcomes. Furthermore, prominent trends for the forecast period include the escalating adoption of her2-targeted antibody therapies, a greater utilization of antibody-drug conjugates, the expansion of companion diagnostic testing, an increased emphasis on early-stage targeted treatment, and improved integration of combination therapy approaches.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=89928846&type=smp&name=HER2-Positive%20Breast%20Cancer%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

HER2-Positive Breast Cancer Market Growth Backed By Core Demand Fundamentals

The HER2-positive breast cancer market is projected to grow significantly due to the increasing uptake of immunotherapy. Immunotherapy is a medical approach designed to enhance or modify the immune system’s natural ability to combat diseases such as cancer, infections, and autoimmune disorders. Its widespread adoption is attributed to its capacity to bolster the immune system’s ability to identify and eliminate cancer cells, offering superior efficacy and fewer side effects compared to conventional treatments. Specifically for HER2-positive breast cancer, immunotherapy aids by strengthening the body’s immune system to recognize and attack HER2-overexpressing cancer cells, leading to improved treatment outcomes and a reduced risk of recurrence. For instance, in July 2023, the American Association for Cancer Research, a US-based organization, noted that by 2023, the FDA had approved 11 immune checkpoint inhibitors (ICIs), with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Therefore, the robust adoption of immunotherapy is a key driver for the expansion of the HER2-positive breast cancer market.

HER2-Positive Breast Cancer Market Segment Landscape And Growth Outlook

The her2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation

5) By Other Treatment Types: Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

#HER2-Positive Breast Cancer Market Growth Trends: What’s Shaping The Future Outlook?

Major companies operating within the HER2-positive breast cancer market are concentrating on developing innovative therapies, including HER2-directed antibody-drug conjugates (ADCs), to optimize and enhance patient treatment processes. These HER2-directed antibody-drug conjugates (ADCs) are precise cancer treatments that link an antibody specific to HER2 with a cytotoxic drug, ensuring the medication is delivered directly to HER2-positive cancer cells for improved effectiveness. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This groundbreaking therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. As a HER2-directed antibody-drug conjugate (ADC), Trastuzumab deruxtecan delivers a cytotoxic drug straight to HER2-positive cancer cells, offering a more targeted and efficacious treatment for patients.

HER2-Positive Breast Cancer Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

View The Full HER2-Positive Breast Cancer Market Report:

https://thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

HER2-Positive Breast Cancer Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-positive breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model